×

Biotech and Pharmaceuticals Medicine

  • Gabriella Corley

    Soaring insulin prices and inflexible insurance policies have forced many parents to take desperate measures to keep their kids alive.

  • The pills, creams and teas are untested and not approved by the FDA, which called them a "cruel deception." The FDA on Tuesday posted the warning letters it sent to 14 manufacturers, telling them to remove their fraudulent claims describing the products as drugs, or face stiff penalties. "Anyone who suffers from cancer, or know someone who does, understands the fear and...

  • Lilly reiterated that it was disappointed and disagreed with the FDA assessment on baricitinib, particularly since the medicine won European approval. On a conference call with analysts, Lilly was asked whether it was likely in 2017 or 2018 to satisfy FDA concerns outlined in the letter denying approval. "We can't give an estimate on this year or next until we...

  • However, the Indianapolis- based drugmaker has suffered setbacks recently, with the U.S. Food and Drug Administration earlier this month declining to approve a new drug for rheumatoid arthritis made by Lilly and partner Incyte Corp. The drugmaker on Tuesday posted a net loss of $110.8 million, or 10 cents per share, in the first quarter, compared with a profit of...

  • Tim Wentworth, CEO of Express Scripts.

    The fact that Anthem wants to cut ties with Express Scripts is "perplexing," Express Scripts CEO Tim Wentworth told CNBC on Monday.

  • Shares of Indianapolis- based Lilly, which is scheduled to report its first-quarter results on Tuesday, were up 1.3 percent at $82.95 on Monday. Lilly's drug, abemaciclib, is likely to compete with market leader Pfizer Inc's Ibrance, which brought in $2.1 billion in 2016 sales, and Novartis AG's newly approved Kisqali. "This is an unexpected win for Lilly," Leerink...

  • Behind the $24 billion medical device deal

    CNBC's Meg Tirrell reports the latest on the deal between Becton Dickinson and C.R. Bard.

  • The outside of the Food and Drug Administration headquarters is seen in White Oak, Md., on Monday, November 9, 2015.

    South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade.

  • The U.S. Food and Drug Administration approved Renflexis, developed by Samsung Bioepis Co. of South Korea. Its U.S. partner, Merck& Co. of Kenilworth, New Jersey, will market Renflexis. The first biosimilar for Remicade, Inflectra from New York- based Pfizer Inc., went on sale in November at a 15 percent discount.

  • The Food and Drug Administration said Friday that it approved Renflexis, developed by Samsung Bioepis Co. of South Korea. It will be marketed by its U.S. partner, Merck& Co. of Kenilworth, New Jersey. Without insurance, Remicade generally costs more than $30,000 annually for adults; dosage varies with the patient's weight.

  • April 21- A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis. The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis.

  • April 21- Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.. Taltz is priced at about $6,000 per month, while Cosentyx at $5,400 per month as per the recommended dosing schedules, she said.

  • April 21- Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.. Drugmakers are facing intense criticism from politicians, insurance companies and patient advocacy groups in the United States over the...

  • April 20- Doctors have struggled for years to deliver medication effectively to the inner ear, but two companies are vying to be first to introduce new treatments which, if successful, could together chalk up some $800 million in peak sales. Darius Kohan, chief of otology/neurotology at New York- based Lenox Hill Hospital. San Diego- based Otonomy and Swiss biotech...

  • April 19- AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies. The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer and triple-negative breast cancer. Tesaro's niraparib won the U.S. Food and Drug...

  • April 19- AbbVie Inc said on Wednesday that its cancer drug, veliparib, failed to meet the main goals of two late-stage studies. The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer and triple negative breast cancer. Veliparib belongs to a closely watched class of new medicines...

  • *Merck, Bristol, Roche also have important upcoming news. LONDON, April 19- Three years after Pfizer's failed bid for AstraZeneca, the British drugmaker aims to prove in the coming weeks that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle. "I think there will be multiple approvals in the first-line space," Naiyer Rizvi,...

  • MIAMI BEACH, Fla.— Thousands of bacteria-infected mosquitoes were released in the wild Tuesday near Key West, testing a new way to kill mosquitoes that carry Zika and other viruses. The infected mosquitoes were flown in cardboard tubes— similar to ones used in paper towel rolls— from Lexington, Kentucky, to Key West on Tuesday morning. At the Stock Island test site,...

  • April 18- Bioelectronic healthcare company electroCore LLC said on Tuesday that the U.S. Food and Drug Administration had approved its hand-held device to treat cluster headaches. The company anticipates the product will be available in the United States in the third quarter. The device, which can be self-administered, is already approved for use in South...

  • For the deaf and hard of hearing, there’s a promising new world of technological innovation.